|
12 Apr 2019 |
FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)
|
|
12 Apr 2019 |
Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
|
|
11 Apr 2019 |
Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019
|
|
11 Apr 2019 |
Intas Pharmaceuticals Launches its Trastuzumab Biosimilar, Eleftha® - Further Bringing Down the Treatment Cost by 65%
|
|
11 Apr 2019 |
Lynparza approved in EU for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer
|
|
10 Apr 2019 |
Sound Biologics Announces FDA Allowance of its IND Application for PSB205, an Anti-PD-1/CTLA-4 MabPair, in Relapsed and Refractory Solid Tumors
|
|
10 Apr 2019 |
FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
|
|
10 Apr 2019 |
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
|
|
10 Apr 2019 |
Synaffix Announces License Agreement Worth up to $125 Million with Leading Chinese ADC Developer, Shanghai Miracogen
|
|
09 Apr 2019 |
BioAtla and BeiGene Form Worldwide Collaboration to Develop and Commercialize Novel Conditionally Active Biologic CTLA-4 Therapy
|
|
09 Apr 2019 |
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
|
|
09 Apr 2019 |
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
|
|
09 Apr 2019 |
Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration
|
|
09 Apr 2019 |
Generium Launches First Biosimilar of Eculizumab; Becomes Fifth Marketed Product Using Selexis SUREtechnology Platform
|
|
09 Apr 2019 |
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application
|
|
09 Apr 2019 |
Translate Bio Presents Preclinical Data Supporting MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting
|
|
09 Apr 2019 |
Enesi Pharma and University of Oxford Collaborate to Target Plague With a Novel ImplaVax®-enabled Adenovirus-based Solid Dose Vaccine
|
|
09 Apr 2019 |
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
|
|
09 Apr 2019 |
PIXUVRI® (pixantrone) Receives Positive CHMP Opinion to Convert Conditional Approval into Standard Marketing Authorization in Patients with Aggressive non-Hodgkin B-cell Lymphoma
|
|
09 Apr 2019 |
LEO Pharma and Elektrofi Expand Partnership to Co-Develop New Antibodies with the Aim of Achieving Improvements in Drug Delivery within Dermatology
|
